The global market for high barrier pharmaceutical packaging films for blister applications is experiencing significant expansion, with forecasts revealing a climb from USD 6 billion in 2025 to USD 8.8 billion by 2035. This uptrend represents a compound annual growth rate (CAGR) of 3.9%, reflecting increased investments and innovations in pharmaceutical packaging technologies. European pharmaceutical companies are central to this growth, as regulatory agencies impose higher standards for drug protection, patient safety, and package integrity, ultimately steering manufacturers toward advanced, quality-driven solutions.

High barrier films, typically used in blister packaging for solid oral dosages, serve as a critical safeguard against environmental threats such as moisture, oxygen, and light exposure. These characteristics are essential in preserving both the potency and shelf life of drugs—a priority for pharmaceutical firms dealing with large-scale production and distribution across Europe’s strictly regulated supply chains. European manufacturers are now intensifying their research and development (R&D) initiatives to innovate new materials and processes, maintaining competitiveness while complying with evolving standards.

Data from 2025 indicates that PVC films remain the most widely used material in this sector, accounting for nearly 47% of market share. The dominance of PVC is attributed to its robust barrier properties combined with cost-effectiveness and widespread industry familiarity. However, next-generation performance-driven films—including PVDC, cold forming aluminum laminates, and multilayer polymer structures—are gaining traction as regulatory guidelines push for higher safety thresholds and more sustainable packaging options.

Regionally, Germany stands out in Europe, registering a CAGR of 4.5% thanks to its focus on novel packaging requirements, technological adoption, and compliance. The United Kingdom invests in upgrading manufacturing efficiency and pharmaceutical compatibility programs (3.3% CAGR), while other European countries are following suit to improve standards and embrace greener practices. The European pharmaceutical sector’s coordinated efforts to meet new compliance challenges drive market-wide adoption of advanced barrier films, making Europe a leader in packaging technology and drug safety.

One of the key drivers behind this market’s momentum is the increasing demand from healthcare systems to ensure medicines remain safe and effective throughout transit and storage, particularly given the complexity of international supply chains. Chronic disease prevalence and the needs of aging populations also shape demand, as long-term medication storage requires high-performing barrier films for both tamper evidence and user convenience. Strategic collaborations are forming among leading players, including Amcor, Klöckner Pentaplast, Constantia Flexibles, Perlen Packaging, Tekni-Plex, Honeywell, and Liveo Research GmbH, along with regional experts such as SÜDPACK and Bilcare. These companies are jointly developing customized solutions tailored to specific drug formulations and diverse climate zones in Europe.

Technological innovation is another critical element, with growing interest in bio-based and recyclable polymers as the sector moves toward a more circular packaging economy. Manufacturers and technology vendors across Europe are rolling out new equipment and machinery engineered for efficiency, quality assurance, and compliance with both EU and national regulatory schemes. For CROs and CMOs, the adoption of innovative films offers opportunities to deliver enhanced value for pharmaceutical partners through improved packaging performance and faster regulatory approvals.

In summary, business leaders and procurement professionals in the European pharmaceutical industry should note that the packaging landscape is evolving rapidly, driven by regulatory shifts, technological progress, and strategic partnerships. The transition toward high barrier and sustainable packaging films is not just a market trend, but a necessity—ensuring that drugs manufactured, stored, and transported within the region meet strict EU requirements for product safety, patient protection, and operational excellence.